Contineum's MOONLIGHT-1 Phase 2 trial fails to hit primary endpoint in depression
JNJ-5120/PIPE-307, licensed to Johnson & Johnson, missed its primary efficacy measure in major depressive disorder, though the company reported no new safety signals.
SEC filing